Marso S.P. et al.
Editor's note
The original CV signal. In 3,297 type-2 diabetics at high CV risk, semaglutide hit non-inferiority and tipped into superiority — a composite event rate of 6.6% vs. 8.9% on placebo. Retinopathy worsened, which is the asterisk you should know about.
Related literature
Lincoff A.M. et al.
The first hard-endpoint cardiovascular outcomes trial of a GLP-1 in non-diabetics. 17,604 patients with prior CV disease and BMI ≥27; 20% relative reduction in MACE at mean 39.8 months. This is the paper that moved semaglutide from a weight-loss drug to a cardiovascular drug.
Jastreboff A.M. et al.
Tirzepatide's coming-out party. At the 15 mg dose, participants lost a mean 22.5% of body weight over 72 weeks across 2,539 adults without diabetes — numbers that approach bariatric-surgery territory and reset every expectation for pharmacotherapy.
Wilding J.P.H. et al.
The trial that turned semaglutide into a household word. 14.9% mean body-weight reduction at 68 weeks vs. 2.4% on placebo across 1,961 adults — the result that opened the floodgates for the entire GLP-1 wave.
Aronne L.J. et al.
The head-to-head everyone was waiting for. 751 adults over 72 weeks: 20.2% weight loss with tirzepatide vs. 13.7% with semaglutide at max tolerated doses — a 6.5-point gap that's clinically meaningful but smaller than the marketing suggests. Both drugs work; tirzepatide works more.
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.